Rheumatoid Arthritis Pipeline Review, H1 2017 [Report Updated: 30062017] Prices from USD $2500

10:29 EDT 5 Jul 2017 | BioPortfolio Report Blog

Rheumatoid Arthritis Pipeline Review, H1 2017


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis Pipeline Review, H1 2017, provides an overview of the Rheumatoid Arthritis Immunology pipeline landscape.

Rheumatoid arthritis RA is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes nonsteroidal antiinflammatory drugs, corticosteroid medications and immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis Immunology, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis Immunology pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in PreRegistration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 17, 27, 48, 62, 7, 223, 52 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 37 and 12 molecules, respectively.

Rheumatoid Arthritis Immunology pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis Immunology.
The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis Immunology by companies and universities/research institutes based on information derived from company and industryspecific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RD brief, MoA other developmental activities.
The pipeline guide reviews key companies involved in Rheumatoid Arthritis Immunology therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Rheumatoid Arthritis Immunology therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis Immunology

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective RD strategies.
Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis Immunology.
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis Immunology pipeline depth and focus of Indication therapeutics.
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.

Original Article: Rheumatoid Arthritis Pipeline Review, H1 2017 [Report Updated: 30062017] Prices from USD $2500


More From BioPortfolio on "Rheumatoid Arthritis Pipeline Review, H1 2017 [Report Updated: 30062017] Prices from USD $2500"

Quick Search


Relevant Topics

Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...